The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy

AIDS

Volumn 20, Issue 4, 2006, Pages 619-621

  Negredo, Eugènia ^a   Clotet, Bonaventura ^a   Puig, Jordi ^a   Pérez Álvarez, Núria ^a   Ruiz, Lidia ^a   Romeu, Joan ^a   Moltó, José ^a   Rey Joly, Celestino ^a   Blanco, Julià ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; CD4 ANTIGEN; STATINE DERIVATIVE; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROLITHIASIS; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; BLOOD; DOSE RESPONSE; PHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPTANOIC ACIDS; HIV INFECTIONS; HIV-1; HUMANS; PILOT PROJECTS; PYRROLES; RNA, VIRAL; VIRUS REPLICATION;

EID: 33645399544     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000210617.90954.0e     Document Type: Article

References (10)

1. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200:541-547.
2. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004; 78:12062-12065.
3. Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Este JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004; 18:1673-1682.
4. Sklar PA, Masur H, Grubb JR, Voell J, Witek J, Ono A, et al. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS 2005; 19:1109-1111.
5. Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, Llano A, et al. Evaluation of the anti-HIV activity of statins. AIDS 2005; 19:1697-1700.
6. Waters L, Stebbing J, Jones R, Mandalia S, Bower M, Stefanovic M, et al. The effect of statins on HIV rebound and blips. J Acquir Immune Defic Syndr 2005; 39:637-638.
7. Campbell SM, Crowe SM, Mak J. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J Clin Virol 2001; 22:217-227.
8. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
9. Braunwald J, Nonnenmacher H, Pereira CA, Kirn A. Increased susceptibility to mouse hepatitis virus type 3 (MHV3) infection induced by a hypercholesterolaemic diet with increased adsorption of MHV3 to primary hepatocyte cultures. Res Virol 1991; 142:5-15.
10. Gower TL, Graham BS. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother 2001; 45:1231-1237.